Real-World Data & Evidence Collection

US network of poison centers and national data system (NPDS) for toxicology and pharmacovigilance surveillance.

WHO primary clinical trial registry for Australia and New Zealand, used for trial discovery and protocol metadata. Psychedelic relevance: registry infrastructure includes psychedelic trial records via search, but no dedicated psychedelic evidence vertical.

Brazil's public clinical trial registry platform for experimental and non-experimental studies in humans. Psychedelic-specific indexing is not offered as a dedicated registry surface.

EU clinical trial public portal with explicit psilocybin trial records currently visible.

WHO primary trial registry for China with broad trial metadata coverage. Psychedelic-specific datasets are not presented as a dedicated public vertical.

Citeline (formerly Informa Pharma Intelligence) is a global pharmaceutical data and clinical intelligence platform providing AI-driven drug pipeline tracking, trial monitoring, and R&D analytics to life sciences organisations. It is referenced as a data source in the Department of Defense PTSD Adaptive Platform Trial involving SLS-002 (esketamine intranasal spray).

Commercial intelligence platform with clinical, regulatory, and real-world evidence datasets for biopharma decision support.

US National Library of Medicine registry and results database with broad global trial coverage, including many psychedelic studies.

European pharmacovigilance system for suspected adverse drug reaction reporting. Psychedelic relevance: EMA has hosted a multi-stakeholder psychedelics regulatory workshop and EudraVigilance is the key EU safety channel.

Erowid Center is a nonprofit educational organization and public information resource on psychoactive substances, including the Erowid Experience Vaults user-report archive and broader harm reduction materials.

Legacy EU clinical trials register still relevant for historical records and legacy IDs linked from CTIS; includes trial history relevant to psychedelic development tracking.

US FDA adverse-event monitoring infrastructure for regulated products. Psychedelic relevance: FDA has issued draft clinical trial guidance for psychedelic drugs and AEMS is the active public safety-monitoring surface.

US FDA adverse-event and product-problem reporting program with public safety communications and reporting channels.

Primary registry for clinical trials in Germany, recognized by WHO as the national primary registry. Psychedelic-specific data is not provided as a dedicated public vertical.

Global anonymous survey platform with explicit psychedelic-use and microdosing self-report outputs in periodic reports.

European catalogues that centralize metadata on real-world data sources and RWD studies for regulatory and research discoverability. These catalogues replaced older ENCePP/EU PAS register-era database surfaces.

National adverse reaction reporting and access database for marketed health products in Canada. Psychedelic relevance: Health Canada publishes psilocybin-specific clinical-trial and special-access policy notices.

Commercial real-world data products and linked evidence assets used in life sciences research and regulatory support.

Primary clinical trial registry with global participation and searchable records including psychedelic-related studies; no dedicated psychedelic-specific product surface.

UK safety reporting program for medicine and device adverse events. Psychedelic relevance: UK has active policy and trial activity, while public MHRA records indicate no authorized psilocybin medicinal product yet.

New Zealand pharmacovigilance infrastructure operated through Medsafe and CARM for adverse-reaction reporting, analysis, and signal monitoring. Public psychedelic-specific dashboards are limited; this profile is included as core safety infrastructure.

National pharmacovigilance centre for the Netherlands supporting adverse drug reaction reporting, signal detection, and patient-reporting channels. Public psychedelic-specific evidence views are limited; this profile is included as core safety infrastructure.

Patient network platform with treatment and condition self-reporting, including explicit psilocybin treatment pages and community-reported outcomes context.

Digital research platform running psychedelic self-report and behavioral studies through app-based participation, including Microdose.me cohorts.

US poison center and toxicology surveillance organization supporting data collection and safety monitoring operations.

Singapore Health Sciences Authority adverse-event reporting framework for therapeutic products and clinical trials. Included as core safety-monitoring infrastructure; no dedicated psychedelic public reporting surface identified.

Swissmedic electronic vigilance infrastructure for adverse drug reaction reporting by healthcare professionals and companies in Switzerland. Included as core safety infrastructure; psychedelic-specific public slices are limited.

Australian adverse-event notification database and safety-monitoring framework. Psychedelic relevance: TGA publishes dedicated policy and access guidance for MDMA and psilocybin use.

WHO collaborating centre for international drug safety monitoring, stewarding VigiBase and global pharmacovigilance methods.

WHO global trial-search aggregator across multiple primary registries. Psychedelic records are present via source registries, but ICTRP does not provide a dedicated psychedelic evidence vertical.